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18F-FES-PET to guide estrogen therapy
ABSTRACT
Whereas anti-estrogen therapy is widely applied to treat estrogen receptor (ER) positive 
breast cancer, paradoxically, also estrogens can induce tumor regression. Up-regulation of ER 
expression is a marker for estrogen hypersensitivity. We therefore performed an exploratory 
study to evaluate positron emission tomography (PET) with the tracer 16α-[18F]fluoro-17β-
estradiol (18F-FES) as potential marker to select breast cancer patients for estradiol therapy. 
Eligible were patients with acquired endocrine-resistant metastatic breast cancer, who 
progressed after ≥2 lines of endocrine therapy. All patients had prior ER positive histology. 
Treatment consisted of estradiol 2 mg, 3 times daily orally. Patients underwent 18F-FES-PET/
CT imaging at baseline. Tumor 18F-FES uptake was quantified for a maximum of 20 lesions 
and expressed as maximum standardized uptake value (SUV
max
). CT-scan was repeated every 
3 months to evaluate treatment response. Clinical benefit was defined as time to radiologic 
or clinical progression ≥24 weeks. Serum tumor markers (CA15.3 and CEA) and serum bone 
turnover markers were serially assessed. 
18F-FES uptake, quantified for 255 lesions in 19 patients, varied greatly between lesions 
(median 2.8; range 0.6–24.3) and between patients (median 2.5; range 1.1–15.5). Seven 
(37%) patients experienced clinical benefit of estrogen therapy, eight progressed (PD), and 
four were non-evaluable due to side effects. The positive and negative predictive value 
(PPV/NPV) of 18F-FES-PET using SUV
max 
>1.5 were 60% (95% CI: 31–83%) and 80% (95% CI: 
38–96%) respectively. Combining 18F-FES-PET/CT with tumor marker response and bone 
turnover markers resulted in a PPV of 100%. 
The high NPV of 18F-FES-PET for response to estradiol therapy deserves further exploration. 
Taking into account tumor markers and bone turnover markers alongside with 18F-FES-PET 
may aid to obtain also a high PPV.
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INTRODUCTION
Until the introduction of tamoxifen, additive estrogens such as the synthetic diethylstilbestrol 
(DES) were considered the hormonal treatment of choice in postmenopausal women. In a 
randomized study in 143 postmenopausal patients with metastatic breast cancer, first line 
endocrine therapy with DES was equally effective as tamoxifen with a response rate of 41% 
vs. 33%. Yet, tamoxifen became the preferred agent because it showed fewer side effects. 
157 An emerging number of anti-estrogen therapies have become available since. Recently, 
however, additive estrogen therapy has regained interest by showing efficacy in ~35% of 
patients that are extensively pre-treated with anti-estrogens. 158 Interestingly an update of 
the randomized study showed a superior 5-year survival for DES compared to tamoxifen 
(35% vs. 16%) after 14 years of follow-up.159 Moreover, in a recent study a lower dose of 
only 6 mg estradiol rendered similar clinical benefit rates as 30 mg estradiol with fewer 
side effects. Finally, clinical results suggest that estrogens can restore the sensitivity to anti-
estrogens.160 As the majority of patients will not benefit from additive estrogen therapy a 
biomarker for patient selection would be helpful. 
In preclinical studies, long-term estrogen deprivation triggered hypersensitivity to estrogens, 
which is accompanied by a 5 to 10-fold increase in ER expression.161,162 Thus, patients 
that have been treated with anti-estrogens for a long time may likewise have become 
hypersensitive to estrogens. If so, patients that are most likely to benefit from estradiol 
therapy could potentially be identified by high tumor ER expression. Positron emission 
tomography (PET) with 16α-[18F]fluoro-17β-estradiol (18F-FES) can visualize and quantify 
ER expression in breast cancer lesions.149 The aim of this exploratory study was therefore 
to evaluate 18F-FES-PET as a potential marker to select breast cancer patients for estradiol 
therapy. 
In the setting of ER positive metastatic breast cancer, response assessment is notoriously 
difficult due to the high incidence of bone metastases. Bone is the most common site 
affected in breast cancer.163 However, bone metastases are regarded non-measurable by 
the response evaluation criteria in solid tumors (RECIST).110 This underlines the need for 
objective measures to predict and evaluate response, for example by molecular imaging 
techniques. Recent studies have shown that 18F-FES-PET can predict response to various 
forms of anti-estrogen therapy.57,63,64,164 Its value as a biomarker for additive estrogen 
therapy is however unknown. 
In addition to molecular imaging techniques, also serum markers may be valuable to assess 
response in patients with bone-dominant disease in which response assessment is difficult. 
The ASCO recommendations for the use of tumor markers in breast cancer indicate that 
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CA 15.3 and CEA can be considered to monitor treatment effects.165 Also, bone turnover 
markers such as procollagen type I amino-terminal propeptide (PINP), carboxyl-terminal 
telopeptide of type I collagen (CTx), and bone alkaline phosphatase (BALP) are reported to 
correlate with the number and size of bone metastases in breast and prostate cancer.166–168 
Therefore, in addition to 18F-FES-PET, we also evaluated whether tumor markers, and bone 
turn over markers can aid response prediction. 
METHODS
Patients
The trial was conducted in accordance with the principles of Good Clinical Practice and the 
Declaration of Helsinki. The protocol was approved by the local medical ethical committee 
and registered in the ClinicalTrials.gov database (NCT01088477). All patients provided 
written informed consent. 
Eligible patients had acquired endocrine-resistant advanced breast cancer showing 
progression ≥2 lines of endocrine therapy. All patients had earlier ER positive 
immunohistochemical tumor staining, and were required to have responded to at least one 
prior line of anti-hormonal therapy (objective response, or stable disease ³6 months). Other 
eligibility criteria were ECOG performance ≤2 and life expectancy ≥3 months. Exclusion 
criteria were the presence of symptomatic central nervous system lesions, a history of 
thrombosis, diabetes mellitus, uncontrolled hypercalcemia, treatment with investigational 
drugs within 30 days before the start of study, dyspnoea at rest due to any cause, and class 
III or IV congestive heart failure according to the New York Heart Association. Patients were 
required to withdraw drugs known to bind ER for at least 5 weeks prior to baseline imaging.50
Estradiol Treatment
Patients were treated with estradiol three times daily 2 mg orally.160 Therapy was initiated 
within 4 days after 18F-FES-PET/CT. In case of toxicity estradiol dosing was reduced to twice 
daily 2 mg, or shortly interrupted with re-introduction at a lower dose when the symptoms 
had resolved. Therapy was continued until progressive disease (PD) by radiologic or clinical 
assessment, withdrawal of consent, or severe toxicity. Toxicity was documented according 
to the Common Terminology Criteria of Adverse Events v3.0.
Assessment of Treatment Response
Baseline measurements included documentation of all symptoms, performance status, 
physical examination, laboratory tests (including blood counts, kidney function, and liver 
enzymes), and a diagnostic CT-scan. Clinical follow-up with documentation of symptoms, 
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performance status, physical examination and laboratory tests were done monthly. A 
diagnostic CT-scan was performed every 3 months until progression. For patients with 
measurable disease, response was defined according to RECIST v1.1.110 Patients with 
only non-measurable lesions were considered to have PD when there was unequivocal 
progression of existing lesions or when new lesions were detected at follow-up. In the 
absence of radiological PD, patients could develop clinical PD, defined as an overall level 
of substantial worsening such that the overall tumor burden or complaints increased 
sufficiently to merit discontinuation of therapy.110 In reference to other studies, patients 
with time-to-progression ≥24 weeks were considered to have obtained clinical benefit from 
estradiol therapy.78
Study Measurements
18F-FES was produced and administered to the patient as described earlier.50,108 On average 
3.4 ± 1.5 GBq 18F-FES was obtained with 100% radiochemical purity and a 325 ± 274 GBq/
µmol specific activity. Patients received approximately 200 MBq 18F-FES intravenously. 
18F-FES-PET/CT to evaluate tumor ER expression was performed at baseline on a hybrid PET/
CT camera with a 64-slice CT and high definition and time-of-flight PET (Siemens Medical 
Systems). Low dose CT scan was used for attenuation correction in all patients. Patients 
were scanned from skull to mid-thigh, 3 minutes per bed position (usually 7-8 bed positions 
per patient). In all patients, baseline 18F-FES-PET was combined with a contrast-enhanced 
diagnostic CT scan. For representative 18F-FES-PET, CT and 18F-FES-PET/CT images see figure 
1. 
Tumor 18F-FES uptake was quantified according to the guidelines of the European Association 
of Nuclear Medicine (EANM).27 Whole-body CT-scan was used to allocate tumor lesions and 
identify possible 18F-FES negative lesions. Lesion 18F-FES uptake was expressed as maximum 
standardized uptake value (SUV
max
). For patient-based analysis, the median 18F-FES uptake of 
an arbitrary maximum of 20 lesions was calculated. Quantification of tumor 18F-FES uptake 
was performed while blinded for treatment outcome. Patients and treating physician were 
held blinded for 18F-FES-PET results.
Tumor markers (CA-15.3, CEA) and bone turnover markers (PINP, CTx and BALP) were also 
determined at baseline, and repeated every 3 months or at the time of progression. Patients 
were considered evaluable for tumor marker response if one of both tumor markers were 
increased at baseline (CA15.3 >33 kU/L, CEA >5 μg/L). A 10% decrease in tumor marker was 
scored as -1, an increase of 10% as +1 and between -10 and +10% was scored 0. A sum of 
scores of <1 was defined as biochemical tumor marker response, and a sum of scores ≥1 as 
non-response. Patients were considered evaluable for bone turnover markers when they 
84
Chapter 5
18F-FES-PET to guide estrogen therapy
had evidence of bone metastases on imaging. Serum PINP >95 ng/mL was considered the 
threshold for increased bone turnover based on literature.168 For CTx and BALP the optimum 
thresholds were determined by receiver operating characteristic (ROC) analysis. 
Statistical Analysis
The expected study time frame was 3 years for inclusion of 50 patients, to evaluate the 
positive predictive value (PPV) and negative predictive value (NPV) of 18F-FES-PET/CT by ROC 
analysis. After 3 years and 21 patients included, the study was terminated. We here report 
the PPV and NPV for 18F-FES-PET/CT, which was the predefined primary end point of the 
study. PPV and NPV were calculated using a ROC analysis for the median tumor SUV
max 
in 




Figure 1. 18F-FES-PET (A), CT (B) and fused 18F-FES-PET/CT (C) images of a patient with bone metastases. Indicated is 
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Table 1: Patient characteristics
Baseline characteristics All patients (n=19)
Male : female 1 : 18
Age, mean years (range) 57 (36-76)
Site of metastases, n







Prior systemic therapies, n
<3 lines 1






and bone turnover markers and benefit from estradiol, calculated by a Mann-Whitney 
U test. PPV and NPV were determined for these markers alone and in combination with 
18F-FES-PET/CT findings. Analyses were performed in SPSS Statistics version 20.0.
RESULTS
Patient Characteristics
Between May 2010 and May 2013, 30 patients were screened for participation in the trial, 
out of whom 21 were included and 19 started estradiol therapy, one male and 18 females. 
Mean age was 57 years (range 36–76). Seventeen patients had bone metastases, in 14 
patients accompanied by also visceral or nodal metastases. Two patients had only visceral 
lesions. All patients had postmenopausal status, which was in two patients achieved by 
the use of LHRH agonists, while others were truly postmenopausal. Tumor histology was 
positive for ER in all patients, 12 (63%) were also PR positive, and none were HER2 positive. 
All patients were heavily pre-treated; 11 patients had already received 3-4 lines of systemic 
therapy, and 7 patients ³5 lines. Patient characteristics are summarized in table 1. For an 
overview of screening, inclusion and exclusion see the CONSORT diagram (figure 2). 
Tumor Response
Twelve patients had measurable lesions on baseline CT according to RECIST, four patients 
had non-measurable visceral lesions and three patients had only bone metastases. Four of 
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19 (21%) discontinued estradiol because of side effects and were therefore not evaluable 
for treatment response.
Seven of the remaining 15 patients experienced clinical benefit from estradiol therapy as 
indicated by stable disease ≥24 weeks. Four had radiological measurable stable disease, and 
three patients had no new lesions detected on radiological examination, no progression of 
non-measurable lesions, improvement or stabilization of symptoms, and no evidence of 
biochemical progression ≥24 weeks. They eventually experienced PD according to RECIST 
criteria at 26, 28 and 48 weeks respectively.
Finally, eight patients had PD; in five of them there was radiologic PD and in three patients 
there was substantial clinical deterioration, meriting discontinuation of therapy. One of them 
had laboratory signs of bone marrow invasion, confirmed with a biopsy, one had rising liver 
function tests, a 3-fold increase in tumor marker CA15.3 and clinical deterioration, and one 
Figure 2. CONSORT diagram of all screened (n=30) and enrolled (n=21) patients. CNS = Central nervous system; 
ECOG = Eastern Cooperative Oncology Group; 18F-FES-PET = 16α-[18F]fluoro-17β-estradiol positron emission 
tomography.
Included in the 
study 
(n = 21) 
• Excluded (n = 4) 
   - History of thromboembolic 
      events (n = 1)  
    - Symptomatic CNS lesions 
       (n = 1) 
    - ECOG performance status 
       >2 (n = 2) 
• Did not provide consent or 




(n = 20) 
• Developed symptomatic brain 
  metastases prior to 18F-FES 




(n = 19) 
• Brain metastases on 18F-FES 
  PET which appeared to be 
  symptomatic after neurological 




(n = 30) 
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patient had deterioration of pain symptoms from bone lesions, rising alkaline phosphatase 
and worsening of performance score. Overall clinical benefit rate was 37% in all treated 
patients (intention-to-treat; n=19 patients). Mean progression-free-survival was 4.7 months 
(range 0.4–15.3 months). Estradiol therapy induced an increase in serum estradiol levels 
from 89 ± 15 pmol/L at baseline to 1241 ± 225 pmol/L after 1 month of therapy. The increase 
in estradiol levels was equal among responders and non-responders.
Toxicity
In four patients (21%) estradiol therapy was terminated prematurely due to adverse events. 
These side effects were progressive thrombocytopenia (n=1), transient ischemic accident 
with atrial fibrillation (n=1), mood disorders (n=1) and signs of congestive heart failure 
(n=1). Other grade 3 serious adverse events requiring hospital admission were tumor 
flare (n=1), hypercalcemia (n=2), pneumonia (n=1) and atrial fibrillation (n=1). The patient 
who experienced a tumor flare had rapid increase of pain symptoms at known metastatic 
sites, starting already the day after initiation of estrogen therapy. Laboratory results were 
suggestive of tumor flare with increased lactate dehydrogenase and other liver enzymes. 
Symptoms and laboratory findings resolved after estradiol discontinuation. Interestingly, 





24.3). Common but manageable grade 1-2 adverse 
events were tumor flare, fatigue, nausea, and vaginal bleeding. 
Predictive Value of 18F-FES-PET for Response to Estradiol Therapy
18F-FES uptake in tumor lesions was quantified for a total of 255 lesions (214 bone; 24 lung; 
12 lymph nodes; 1 breast; 1 soft-tissue; and 1 brain lesion) out of which 42 (16%) were 
18F-FES negative (SUV
max 
<1.5). Twelve out of 19 patients (63%) had only 18F-FES positive 
lesions, six (32%) had both 18F-FES positive and 18F-FES negative lesions, and one had only 
18F-FES negative lesions. Absolute 18F-FESuptake (SUV
max
) varied widely between lesions 
(median 2.8; range 0.6–24.3) and patients (median 2.5; range 1.1–15.5), as is depicted in 
figure 3. ROC analysis indicated that the most optimum threshold to differentiate between 
patients with clinical benefit and patients with PD was a median SUV
max
 of >1.5. This 
threshold produced a PPV of 60% (95% CI: 31–83%) and a NPV of 80% (95% CI: 38–96%) 
(figure 4A), with an area under curve of 0.62.
Nine patients terminated treatment with ER antagonists 5 weeks before initiating estrogen 
therapy. Three patients of them had an earlier 18F-FES-PET obtained in another study 
(NCT01377324). These patients had much lower18F-FES uptake than on the earlier scans 
and several lesions could no longer be observed. For example, one patient had on earlier 
18F-FES-PET a median tumor 18F-FES uptake of 6.5, while in the current study SUV 
max
 was only 
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1.1. This patient benefited from estradiol despite the relatively low tumor 18F-FES uptake. 
The remaining six patients had no earlier scans available, but also had relatively low tumor 
18F-FES uptake compared to patients without recent use of drugs that can bind ER. Thus, 
ER antagonists may reduce tumor 18F-FES uptake beyond the currently used 5-week drug 
withdrawal period.50 In an explorative analysis, using the results of the previous 18F-FES-
PET scans instead of the current PET scans, the PPV and NPV increased to 64% and 100%, 
respectively (figure 4B).
Additive Value of Serum Markers
Two patients had normal tumor markers at baseline, leaving 17 patients evaluable for 
tumor markers. A response was seen in seven patients. The PPV and NPV for tumor marker 
response were 67% and 71%, respectively. Tumor marker response added to 18F-FES-PET 
results provided a PPV of 100% for 18F-FES positive patients with a tumor marker response 
and a NPV of 66% for 18F-FES negative patients with a non-response in tumor markers (table 
2).
Figure 3. 18F-FES uptake (SUV
max
) in the tumors is depicted for all quantified lesions for bone, lung, nodal and other 
lesions. Patients are listed on the x-axis.
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Table 2: Association between 18F-FES-PET, tumor markers, bone turnover markers, and treatment outcome
Marker Result n Response Classification Predictive value
CB PD NE PPV NPV
18F-FES-PET* Positive 10 6 4 (4) 60%
 Negative 5 1 4 (0) 80%
Tumor marker Response 6 4 2 (1) 67%
Non response 7 2 5 (3) 71%
Not evaluable 2 1 1 (0)
Combined PET + tumor marker PET+/ Response 4 4 0 (1) 100%
 PET-/ No response 3 1 2 (0) 66%
Bone marker Normal 5 5 0 (1) 100%
PINP Increased 8 1 7 (3) 88%
Not evaluable 2 1 1 (0)
Combined PET + Bone marker PET+/ normal PINP 5 5 0 (0) 100%
PET-/ increased PINP 4 0 4 (1) 100%
Abbreviations: CB = clinical benefit, PD = progressive disease, NE = non-evaluable, PPV = positive predictive value, 
NPV = negative predictive value, 




Bone turnover markers were explored as potential effect sensors in patients with bone 
metastases. Mean levels were 175 ng/mL for PINP (range 17–613 ng/mL), 90 U/L for BALP 
(range 27–298 U/L), and 467 pg/mL for sCTx (range 26–1369 pg/mL). Change in bone 
turnover markers was not associated with treatment response. However, the baseline 
Figure 4. (A) Association between median 18F-FES uptake (SUV
max
) in the tumors per patient and treatment outcome. 
Patients with clinical benefit (CB), progressive disease (PD) and non-evaluable (NE) patients are indicated. The 
dashed line indicates the 1.5 (SUV
max
) threshold as determined by receiver operating characteristic analysis. One 
patient is not shown in the figure (indicated by *) as her median 18F-FES uptake in tumors was much higher (median 
SUV
max 
15.5). Patients indicated in white had recently been treated with ER antagonists. (B) ER antagonists may 
falsely induce 18F-FES negative results. In three patients, indicated in gray, a previous 18F-FES-PET scan was available 
from another study (NCT01377324). Using this scan results in an improvement of the PPV and NPV.
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values were strongly associated with time-to-progression. Baseline PINP levels were 85 vs 
234 ng/mL (P = 0.032), and sCTx levels 195 pg/mL vs. 623 pg/mL (P = 0.032) in patients with 
clinical benefit and PD, respectively. The PPV and NPV for PINP were 100% (5/5 patients) 
and 88% (7/8 patients) for PINP ≤95 ng/mL.168 PPV and NPV were 100% (4/4 patients) and 
78% (7/9 patients) for sCTx levels >200 pg/mL. BALP levels were non-informative in this 
exploratory study. The addition of PINP to 18F-FES-PET/CT results increased both PPV and 
NPV values to 100%.
DISCUSSION
This is the first exploratory study evaluating 18F-FES-PET/CT as predictive marker for estradiol 
therapy in patients with metastatic endocrine resistant breast cancer. While the mechanism 
of anti-estrogen therapy is well known, this is not the case for the addition of estrogens. 
Based on preclinical data, we hypothesized that very high 18F-FES uptake would predict 
response to estradiol therapy. The value of 18F-FES-PET, however, turned out to be especially 
its ability to identify patients that are unlikely to benefit from estradiol therapy as a result of 
low or absent 18F-FES uptake in metastases. 
There are currently no good upfront predictive biomarkers to select patients for estradiol 
therapy. Assessing ER status by a biopsy is the current golden standard, but is sometimes 
unreliable due to heterogeneous ER expression within and among lesions, and detection of 
non-functional ER. 2’-[18F]fluoro-2’-deoxyglucose (18F-FDG) PET imaging has been tested to 
predict response to estradiol therapy. A study randomized 66 patients to 6 or 30 mg estradiol 
daily, 43 patients underwent 18F-FDG-PET imaging before and 24 h after the initiation of 
estrogen therapy.160 A metabolic flare reaction upon estradiol therapy, predefined as a 
≥12% increase in tumor 18F-FDG uptake, had a PPV of 80% (12 of 15 patients) and a NPV 
of 87% (27/31 patients) for response to estradiol therapy. Metabolic flare on 18F-FDG-PET 
in 51 patients subsequently treated with an aromatase inhibitor or fulvestrant had an 
even higher PPV and NPV of 100% and 94%.57 18F-FES-PET was evaluated earlier in three 
studies as predictive biomarker before the initiation of aromatase inhibitors, tamoxifen or 
fulvestrant. In these studies, the PPV of 18F-FES-PET ranged between 32% and 79% and the 
NPV between 82% and 100%.57,63,64 which is comparable with our findings. It is hypothesized 
that a negative 18F-FES-PET can identify tumors that have lost ER expression during the 
course of disease.57,63,64,149 Recently, ESR1 (ER) gene mutations have been described, some 
of which strongly reduce ligand binding affinity and induce endocrine resistance.169 These 
phenomena might explain the good NPV of low tumor uptake of 18F-FES. 
Our study has some limitations. First, the number of patients included was lower than 
expected. A possible explanation is that, despite the fact that previous studies have shown 
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the safety and benefits of estradiol therapy, physicians may be reluctant to refer patients for 
estrogen therapy given that anti-estrogen therapy is the key method to treat patients with ER 
positive disease. Secondly, we used CT to identify 18F-FES negative lesions. It is possible that 
18F-FDG-PET together with 18F-FES-PET increases the sensitivity for 18F-FES negative lesions, 
since especially bone lesions are difficult to characterize on CT. Finally, when evaluating the 
predictive value of 18F-FES-PET, it is important to take concomitant and recent therapies 
into account. We observed low 18F-FES uptake in several previously 18F-FES-avid lesions in 
patients that had used ER antagonists up to 5 weeks before 18F-FES-PET. Possibly, the long 
half-lives (t½) of fulvestrant (t½ = 40 days) and of tamoxifen and metabolites (t½ = 9 and 13 
days, respectively) could be responsible for the 18F-FES negative results.170–172 In the absence 
of biopsies, we are however unable to fully dissect whether the observed effects can be 
attributed to altered ER expression or to spill over effects of recent therapies.
In preclinical studies long-term estrogen deprived ER positive breast cancer cells are 
used to study estrogen-induced apoptosis. After several months of culturing in estrogen-
deprived conditions, breast cancer cells adapt to the low levels of estrogens by increasing ER 
expression.173,174 Paradoxically, therapeutic doses of estrogens now no longer induce growth 
proliferation, but induce apoptosis. More recently, ESR1 gene amplification was described 
in patient-derived mouse xenografts as a possible marker for hypersensitivity to estradiol.175 
It would therefore be of interest in future studies to combine 18F-FES-PET/CT with analysis 
of ESR1 gene amplification and mutation in tumor biopsies, in order to potentially improve 
the selection of patients for estrogen therapy. 
Although ER expression is required for response to endocrine agents, ER positive tumors 
may still fail to respond, e.g. due to cross talk with other pathways. We therefore evaluated 
whether the addition of tumor and bone turnover markers could improve response 
prediction. The association of tumor marker response alone with the patient response 
classification was modest, but when tumor marker response was combined with 18F-FES-PET 
the PPV increased to 100%. Clearly, the number of patients in this study was only limited 
and therefore this observation should be further evaluated in larger studies. The same 
effects were observed for bone turnover markers, which in this limited number of patients 
performed better than 18F-FES-PET alone. Surprisingly, not the changes in bone markers 
during treatment, but the pre-treatment values were associated with time-to-progression. 
These markers are known to correlate with the number and size of bone metastases in 
breast and prostate cancer.166–168 Therefore, high serum bone markers may be useful to 
identify patients that have a poor prognosis independent of the therapy given. Whether 
bone markers are of prognostic or predictive value needs to be addressed in larger studies, 
adhering to REMARK criteria.176
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We observed a clinical benefit rate of 37% for estradiol 6 mg orally daily, which is 
comparable to the study by Ellis et al.160 Our study is the second evaluating this low-dose 
regimen, as compared to the previously standard of 30 mg orally daily. The clinical benefit 
rate observed in our study in patients that were extensively pre-treated (median of 4 prior 
regimens) provides further evidence for the efficacy of estradiol 6 mg daily. The 21% of 
patients that terminated treatment prematurely due to toxicity was relatively high; grade 3 
adverse events were noted in 42% of the patients. The high incidence of toxicity, however, 
underlines the value of upfront predictive markers for this treatment. 
CONCLUSION
Patients with acquired endocrine resistant metastatic breast cancer may paradoxically 
benefit from estradiol therapy. The relatively low response rate and toxicity accompanying 
estradiol therapy warrants exploration of potential biomarkers to predict response. 18F-FES-
PET may aid to identify patients that are unlikely to respond to estradiol therapy. The 
addition of other markers, such as bone turn over markers and tumor markers may aid to 
obtain also a good positive predictive value. 
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